Circulating Tumor Cells as a Marker of Disseminated Disease in Patients with Newly Diagnosed High-Risk Prostate Cancer
Wojciech A. Cieślikowski(Poznan University of Medical Sciences), Andrzej Antczak(Poznan University of Medical Sciences), Monika Świerczewska(Heliodor Swiecicki Clinical Hospital), Agnieszka Jankowiak(Poznan University of Medical Sciences), Catherine Alix‐Panabières(Hamburg Institut (Germany)), Klaus Pantel(Universität Hamburg), Piotr Milecki(Poznan University of Medical Sciences), Michał Hrab(Poznan University of Medical Sciences), M. Zabel(Poznan University of Medical Sciences), Joanna Budna(Poznan University of Medical Sciences), Martine Mazel(Université de Montpellier), Michał Nowicki(Poznan University of Medical Sciences), Agnieszka Ida(Poznan University of Medical Sciences)
Cited by 41
Related Papers
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
|British Journal of Cancer|2020|402
Hemodynamic Forces Tune the Arrest, Adhesion, and Extravasation of Circulating Tumor Cells
|Developmental Cell|2018|328
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268